 NEW YORK, May 06, 2021 GLOBE NEWSWIRE -- Cellectis S.A. NASDAQ: CLLS EURONEXT GROWTH: ALCLS the Company, a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic chimeric antigen receptor CAR T-cells in the field of immuno-oncology, today announced its results for the three-month period ending March 31, 2021. 